Skip to content

H.R. 7539 · 118th Congress (2023–2025)

LOANS for Biomedical Research Act

This bill requires the Department of the Treasury to establish the BioBonds Program to support loans for clinical trials for eligible drugs and medical devices for unmet medical needs.

Under the program, fiscal agents purchase loans (up to $25 million per recipient) and issue collateralized bonds that are sold to investors and that are guaranteed by Treasury. An eligible borrower under this program is one conducting (or seeking to conduct) research related to a drug or device that is (1) intended to meet an unmet medical need; and (2) under investigation in certain types of controlled clinical trials, including a trial to investigate the safety and effectiveness of the drug or device.

The Government Accountability Office (GAO) and Treasury must report on the program; GAO must also study whether similar programs should be established for other biomedical research projects.

Show official title

To require the Secretary of the Treasury to guarantee BioBonds in order to provide funding for loans to eligible biomedical companies and universities to carry out clinical trials approved by the Food and Drug Administration, and for other purposes.

Expired in House committee

Derived from the legislative history, not an official disposition.

Latest actionReferred to Health

This bill’s path

This is H.R. 7539’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed House

  3. Passed Senate

  4. Sent to President

  5. Signed into law

  6. Expired

Sponsor
Rep. Brian K. Fitzpatrick (R-PA-1)
Cosponsors
8 cosponsors

1 original · 7 later

2 R · 6 D

  1. Rep. Sanford D. Bishop, Jr. (D-GA-2)· Original · Mar 5, 2024
  2. Rep. Pete Sessions (R-TX-17)· Later · Apr 18, 2024
  3. Rep. Jill N. Tokuda (D-HI-2)· Later · May 6, 2024
  4. Rep. Adrian Smith (R-NE-3)· Later · May 22, 2024
  5. Rep. Josh Gottheimer (D-NJ-5)· Later · Jun 25, 2024
  6. Rep. Brendan F. Boyle (D-PA-2)· Later · Jun 26, 2024
  7. Rep. Mike Levin (D-CA-49)· Later · Jul 26, 2024
  8. Rep. Bradley Scott Schneider (D-IL-10)· Later · Aug 20, 2024
Policy area
Health

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in House

    Document: Introduced in House

    Sources
  2. Latest
    ▸ 2 committee actions · Mar 5, 2024 – Mar 8, 2024
    1. Referred to committee

      Referred to the House Committee on Energy and Commerce.

      Sources
    2. Referred to Health

      Referred to the Subcommittee on Health.

      Sources
  3. Expired

    Introduced → Referred to House Health → No further action before the 118th Congress ended.

Committees

  1. HouseEnergy and CommerceReferred Mar 5, 2024
  2. HouseHealthReferred Mar 8, 2024

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in House
Titles (3)
  1. LOANS for Biomedical Research Act

    Display title, Short title · Introduced in House

  2. Long-term Opportunities for Advancing New Studies for Biomedical Research Act

    Short title · Introduced in House

  3. To require the Secretary of the Treasury to guarantee BioBonds in order to provide funding for loans to eligible biomedical companies and universities to carry out clinical trials approved by the Food and Drug Administration, and for other purposes.

    Official title · Introduced in House